Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: Ted The Technician who wrote (482)	11/29/1998 11:37:00 PM
From: Steve Research	Respond to of 569

re:next Q's sales.....I would have to think huge. Last Q's sales were only with Synvisc being produced for a just a few days. 4Q98 should come in at .53 cents says Prudential. Here is a perfect company: Biotech, other products in the pipeline AND they are making money! Buy the stock........

To: Ted The Technician who wrote (482)	11/29/1998 11:43:00 PM
From: Steve Research	Read Replies (1) \| Respond to of 569

1999 product sales: According to Pru: 1999 product sales:they are supposed to sell 2 million syringes for product sales of $92.5 million, they have this market to themselves over the next two years with NO COMPETITION! I am unsure of what they are looking for in product sales for 4Q 98. Sounds like a Peter Lynch stock to me: 1- They earn money 2- earnings multiple WAY lower than growth rate 3- No competition 4- Huge demand for product. A two bagger by end of 1999